JAZZ
Jazz Pharmaceuticals Plc
NASDAQ · Pharmaceuticals
$165.50
+2.35 (+1.44%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 3.75B | 3.42B | 1.71B | 1.73B | 1.70B |
| Net Income | 515.64M | 423.58M | 431.71M | 500.28M | 414.07M |
| EPS | — | — | — | — | — |
| Profit Margin | 13.8% | 13.1% | 25.3% | 28.9% | 24.4% |
| Rev Growth | +9.6% | +9.6% | +7.0% | +7.8% | +14.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 3.01B | 3.01B | 3.01B | 3.35B | 3.35B |
| Total Equity | 2.02B | 2.02B | 7.21B | 6.96B | 7.49B |
| D/E Ratio | 1.49 | 1.49 | 0.42 | 0.48 | 0.45 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 1.24B | 1.07B | 625.64M | 730.31M | 605.53M |
| Free Cash Flow | — | — | 246.64M | 376.40M | 328.43M |